ContraFect

ContraFect Dividend Growth

Year-over-Year Dividend Growth of ContraFect (CFRXQ) as of Oct 18, 2026.

Dividend Growth

-

Last updated:

Year-over-Year Dividend Growth of ContraFect is 2026 - . Year-over-Year Dividend Growth of ContraFect was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

On Eulerpool you can find the complete historical development of Year-over-Year Dividend Growth ContraFect since 2006 – with annual values, charts, and detailed analysis.

Dividend growth measures the percentage increase in dividends compared to the previous year. Consistent dividend growth signals financial strength and shareholder commitment.

To evaluate Year-over-Year Dividend Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Dividend Growth.

Year-over-Year Dividend Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Dividend Growth's ContraFect historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ContraFect

All Key Metrics — ContraFect